Effects of N-acetylcysteine on Th1/Th2 balance in patients with chronic obstructive pulmonary disease
10.12025/j.issn.1008-6358.2018.20171048
- VernacularTitle:口服N-乙酰半胱氨酸对稳定期慢性阻塞性肺疾病患者Th1/Th2平衡的影响
- Author:
Jing WANG
1
;
Chun-Feng PAN
;
Zhi-Xiong HU
;
Hai-Ying ZHOU
Author Information
1. 复旦大学附属金山医院呼吸科
- Keywords:
chronic obstructivpulmonardisease;
N-acetylcysteine;
Th1/Th2
- From:
Chinese Journal of Clinical Medicine
2018;25(2):270-274
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To assess the efficacy of N-acetylcysteine on Th1/Th2 balance in patients with chronic obstructive pulmonary disease(COPD).Methods:In our study,we enrolled 80 COPD patients aged 60-85 years old with type C and D.The patients were randomly allocated to receive N-acetylcysteine(one 600 mg tablet,twice daily)or placebo for 6 months.ELISA was used to detect the expression of interferon-γ(IFN-γ)and interleukin-4(IL-4).Flow cytometry was used to compare the rate of Th1/Th2.The rate,duration and the severity of the exacerbation were compared between the two groups throughout the course of treatment.Results:Compared with the placebo group,patients treated with N-acetylcysteine had less acute exacerbation rate,duration time and the Ⅱ or Ⅲ grade severity acute exacerbation,the difference was statistically significant(P<0.05).The levels of IL-4 and Th2/CD4+T cell were significantly higher while the levels of IFN-γ and the Th1/CD4+T cell and Th1/Th2 were significantly lower in N-acetylcysteine group than those in the placebo group after 6 months treatment,the same results were observed compared with that before the treatment(P<0.05).There was no difference of the IL-4,IFN-γ,Th1/CD4+T cell,Th2/CD4+T cell and Th1/Th2 level in placebo group before and after the treatment. Conclusions:Our study shows that in elderly COPD patients with group C and D,long-term use of 1 200 mg N-acetylcysteine can balance the rate of Th1/Th2 and prevent exacerbation,shorten the duration,and decrease the severity of exacerbation.
